Thrombolysis with tissue plasminogen activator (tPA) provides the most common therapy for
ischemic stroke onset within the past 4.5 h. However, enhanced neutrophil infiltration and …

Ischemic stroke caused by a thrombus clog and ischemia is one of the most lethal and
disabling cerebrovascular diseases. A sequentially targeted delivery system is highly …

Rational design of nanomedicine to accelerate thrombolysis and sequentially avoid
thrombolysis-mediated reperfusion injury is still a challenge. Here, we develop a biomimetic …

In acute ischemic stroke, neutrophils contribute to ischemia-reperfusion injury through
producing neutrophil extracellular traps (NETs), which promote the interaction of platelets …

Thromboembolic stroke is typically characterized by the activation of platelets, resulting in
thrombus in the cerebral vascular system, leading to high morbidity and mortality globally …

Rapid cut‐off of blood supply in diseases involving thrombosis is a major cause of morbidity
and mortality worldwide. However, the current thrombolysis strategies offer limited results …

Due to the mortality associated with thrombosis and its high recurrence rate, there is a need
to investigate antithrombotic approaches. Noninvasive site-specific thrombolysis is a current …

Thrombotic cardio‐cerebrovascular diseases seriously threaten human health. Currently,
conventional thrombolytic treatments are challenged by the low utilization, inferior thrombus …

Brain inflammation is regarded as one of the leading causes that aggravates secondary
brain injury and hinders the prognosis of ischemic stroke. After ischemic stroke, high …

Due to the high morbidity and mortality of cardiovascular diseases, there is an urgent need
for research on antithrombotic strategies. In view of the short half-life, insufficient drug …